PU25.01	Social disclosures in relation to perceived HIV protection provided by the dapivirine vaginal ring	Publication Only	Preclinical studies for HIV prevention
PE25.01	What women want in a multipurpose vaginal ring: findings from a phase 1 trial in the U.S. and the Dominican Republic	E-poster	Product acceptability and adherence
PE25.02	Impact of women's home environment on use of the dapivirine ring for HIV prevention in MTN-025/HOPE	E-poster	Product acceptability and adherence
PE25.03	Patterns of adherence among South African women in a phase III randomized controlled trial of a dapivirine vaginal ring for HIV-1 prevention	E-poster	Product acceptability and adherence
PE25.05	Utilization patterns and HIV incidence within the first year of initiation of FTC/TDF for HIV pre-exposure prophylaxis (PrEP) among insured persons in the US	E-poster	Product acceptability and adherence
PE25.06	PrEP adherence is associated with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe	E-poster	Product acceptability and adherence
PE25.07	End-users' hypothetical acceptability of a biodegradable implant to prevent HIV and unplanned pregnancy: qualitative insights from South Africa and Zimbabwe	E-poster	Product acceptability and adherence
PE25.08	PrEP use in the HVTN 702 HIV vaccine efficacy trial conducted in South Africa	E-poster	Product acceptability and adherence
PE25.09	Predictors of PrEP discontinuation and refill delays among over 47,000 clients first starting PrEP in Kenya, Lesotho and Tanzania: Implications for programs	E-poster	Product acceptability and adherence
PE25.10	'Men will never take a pill every day if they don't have to': assumptions and realities around acceptability of PrEP among heterosexual men	E-poster	Product acceptability and adherence